Thalidomide for the treatment of esophageal aphthous ulcers in patients with human immunodeficiency virus infection

Jeffrey M. Jacobson, John Spritzler, Lawrence Fox, John L. Fahey, J. Brooks Jackson, Miriam Chernoff, David A. Wohl, Albert W. Wu, Thomas Hooton, Beverly E. Sha, Cecilia M. Shikuma, Laurie A. MacPhail, David M. Simpson, Carol B. Trapnell, Nesli Basgoz

Research output: Contribution to journalArticle

80 Citations (Scopus)

Abstract

A multicenter, double-blind, randomized, placebo-controlled clinical trial was conducted to determine the safety and efficacy of thalidomide for treating esophageal aphthous ulceration in persons infected with human immunodeficiency virus (HIV). Twenty-four HIV-infected patients with biopsy- confirmed aphthous ulceration of the esophagus were randomly assigned to receive either oral thalidomide, 200 mg/day, or oral placebo daily for 4 weeks. Eight (73%) of 11 patients randomized to receive thalidomide had complete healing of aphthous ulcers at the 4-week endoscopic evaluation, compared with 3 (23%) of 13 placebo-randomized patients (odds ratio, 13.82; 95% confidence interval, 1.16-823.75; P = .033). Odynophagia and impaired eating ability caused by esophageal aphthae were improved markedly by thalidomide treatment. Adverse events among patients receiving thalidomide included somnolence (4 patients), rash (2 patients), and peripheral sensory neuropathy (3 patients). Thalidomide is effective in healing aphthous ulceration of the esophagus in patients infected with HIV.

Original languageEnglish
Pages (from-to)61-67
Number of pages7
JournalJournal of Infectious Diseases
Volume180
Issue number1
DOIs
StatePublished - Jul 5 1999
Externally publishedYes

Fingerprint

Aphthous Stomatitis
Thalidomide
Virus Diseases
HIV
Placebos
Therapeutics
Esophagus
Peripheral Nervous System Diseases
Exanthema
Randomized Controlled Trials
Eating
Odds Ratio
Confidence Intervals
Biopsy
Safety

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Immunology

Cite this

Jacobson, J. M., Spritzler, J., Fox, L., Fahey, J. L., Jackson, J. B., Chernoff, M., ... Basgoz, N. (1999). Thalidomide for the treatment of esophageal aphthous ulcers in patients with human immunodeficiency virus infection. Journal of Infectious Diseases, 180(1), 61-67. https://doi.org/10.1086/314834

Thalidomide for the treatment of esophageal aphthous ulcers in patients with human immunodeficiency virus infection. / Jacobson, Jeffrey M.; Spritzler, John; Fox, Lawrence; Fahey, John L.; Jackson, J. Brooks; Chernoff, Miriam; Wohl, David A.; Wu, Albert W.; Hooton, Thomas; Sha, Beverly E.; Shikuma, Cecilia M.; MacPhail, Laurie A.; Simpson, David M.; Trapnell, Carol B.; Basgoz, Nesli.

In: Journal of Infectious Diseases, Vol. 180, No. 1, 05.07.1999, p. 61-67.

Research output: Contribution to journalArticle

Jacobson, JM, Spritzler, J, Fox, L, Fahey, JL, Jackson, JB, Chernoff, M, Wohl, DA, Wu, AW, Hooton, T, Sha, BE, Shikuma, CM, MacPhail, LA, Simpson, DM, Trapnell, CB & Basgoz, N 1999, 'Thalidomide for the treatment of esophageal aphthous ulcers in patients with human immunodeficiency virus infection', Journal of Infectious Diseases, vol. 180, no. 1, pp. 61-67. https://doi.org/10.1086/314834
Jacobson, Jeffrey M. ; Spritzler, John ; Fox, Lawrence ; Fahey, John L. ; Jackson, J. Brooks ; Chernoff, Miriam ; Wohl, David A. ; Wu, Albert W. ; Hooton, Thomas ; Sha, Beverly E. ; Shikuma, Cecilia M. ; MacPhail, Laurie A. ; Simpson, David M. ; Trapnell, Carol B. ; Basgoz, Nesli. / Thalidomide for the treatment of esophageal aphthous ulcers in patients with human immunodeficiency virus infection. In: Journal of Infectious Diseases. 1999 ; Vol. 180, No. 1. pp. 61-67.
@article{9f29c88e6f2c44b7b18b28d8d637def6,
title = "Thalidomide for the treatment of esophageal aphthous ulcers in patients with human immunodeficiency virus infection",
abstract = "A multicenter, double-blind, randomized, placebo-controlled clinical trial was conducted to determine the safety and efficacy of thalidomide for treating esophageal aphthous ulceration in persons infected with human immunodeficiency virus (HIV). Twenty-four HIV-infected patients with biopsy- confirmed aphthous ulceration of the esophagus were randomly assigned to receive either oral thalidomide, 200 mg/day, or oral placebo daily for 4 weeks. Eight (73{\%}) of 11 patients randomized to receive thalidomide had complete healing of aphthous ulcers at the 4-week endoscopic evaluation, compared with 3 (23{\%}) of 13 placebo-randomized patients (odds ratio, 13.82; 95{\%} confidence interval, 1.16-823.75; P = .033). Odynophagia and impaired eating ability caused by esophageal aphthae were improved markedly by thalidomide treatment. Adverse events among patients receiving thalidomide included somnolence (4 patients), rash (2 patients), and peripheral sensory neuropathy (3 patients). Thalidomide is effective in healing aphthous ulceration of the esophagus in patients infected with HIV.",
author = "Jacobson, {Jeffrey M.} and John Spritzler and Lawrence Fox and Fahey, {John L.} and Jackson, {J. Brooks} and Miriam Chernoff and Wohl, {David A.} and Wu, {Albert W.} and Thomas Hooton and Sha, {Beverly E.} and Shikuma, {Cecilia M.} and MacPhail, {Laurie A.} and Simpson, {David M.} and Trapnell, {Carol B.} and Nesli Basgoz",
year = "1999",
month = "7",
day = "5",
doi = "10.1086/314834",
language = "English",
volume = "180",
pages = "61--67",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - Thalidomide for the treatment of esophageal aphthous ulcers in patients with human immunodeficiency virus infection

AU - Jacobson, Jeffrey M.

AU - Spritzler, John

AU - Fox, Lawrence

AU - Fahey, John L.

AU - Jackson, J. Brooks

AU - Chernoff, Miriam

AU - Wohl, David A.

AU - Wu, Albert W.

AU - Hooton, Thomas

AU - Sha, Beverly E.

AU - Shikuma, Cecilia M.

AU - MacPhail, Laurie A.

AU - Simpson, David M.

AU - Trapnell, Carol B.

AU - Basgoz, Nesli

PY - 1999/7/5

Y1 - 1999/7/5

N2 - A multicenter, double-blind, randomized, placebo-controlled clinical trial was conducted to determine the safety and efficacy of thalidomide for treating esophageal aphthous ulceration in persons infected with human immunodeficiency virus (HIV). Twenty-four HIV-infected patients with biopsy- confirmed aphthous ulceration of the esophagus were randomly assigned to receive either oral thalidomide, 200 mg/day, or oral placebo daily for 4 weeks. Eight (73%) of 11 patients randomized to receive thalidomide had complete healing of aphthous ulcers at the 4-week endoscopic evaluation, compared with 3 (23%) of 13 placebo-randomized patients (odds ratio, 13.82; 95% confidence interval, 1.16-823.75; P = .033). Odynophagia and impaired eating ability caused by esophageal aphthae were improved markedly by thalidomide treatment. Adverse events among patients receiving thalidomide included somnolence (4 patients), rash (2 patients), and peripheral sensory neuropathy (3 patients). Thalidomide is effective in healing aphthous ulceration of the esophagus in patients infected with HIV.

AB - A multicenter, double-blind, randomized, placebo-controlled clinical trial was conducted to determine the safety and efficacy of thalidomide for treating esophageal aphthous ulceration in persons infected with human immunodeficiency virus (HIV). Twenty-four HIV-infected patients with biopsy- confirmed aphthous ulceration of the esophagus were randomly assigned to receive either oral thalidomide, 200 mg/day, or oral placebo daily for 4 weeks. Eight (73%) of 11 patients randomized to receive thalidomide had complete healing of aphthous ulcers at the 4-week endoscopic evaluation, compared with 3 (23%) of 13 placebo-randomized patients (odds ratio, 13.82; 95% confidence interval, 1.16-823.75; P = .033). Odynophagia and impaired eating ability caused by esophageal aphthae were improved markedly by thalidomide treatment. Adverse events among patients receiving thalidomide included somnolence (4 patients), rash (2 patients), and peripheral sensory neuropathy (3 patients). Thalidomide is effective in healing aphthous ulceration of the esophagus in patients infected with HIV.

UR - http://www.scopus.com/inward/record.url?scp=0032977309&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032977309&partnerID=8YFLogxK

U2 - 10.1086/314834

DO - 10.1086/314834

M3 - Article

C2 - 10353862

AN - SCOPUS:0032977309

VL - 180

SP - 61

EP - 67

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 1

ER -